Biologic medicines such as insulin and GLP-1 therapies remain costly and technically complex to manufacture.
R&D Focus
Insulin and GLP-1 biologics and biosimilars
Innovative Solution
Virtu Pharmako is a Sino-foreign joint venture biopharmaceutical business focused on the manufacturing of biosimilars, novel biological pharmaceuticals, and biological products represented by insulin and GLP-1 receptor agonists.
Investment Funding
Last Funding Stage
Series A
Total Funding Amount
35.13M
Last Funding Amount
35.13M
Last Funding Date
30-10-2024
Startup Stage
Early Stage
Lead Investors
Zhangkelingyi
About
Virtu Pharmako is a Sino-foreign joint venture biopharmaceutical business focused on the manufacturing of biosimilars, novel biological pharmaceuticals, and biological products represented by insulin and GLP-1 receptor agonists.
Products
Product
Biosimilar and novel biologic products based on insulin and GLP-1 receptor agonists.
Demo Product or Complete Product?
Development-stage technology or ingredient platform; commercialization or clinical development is ongoing.
Something missing or incorrect on this page? Help us enrich this information
